Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-ε4 Allele

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Monoclonal antibodies (mAbs) show promise for Alzheimer's disease (AD) treatment.
• Adverse effects, including Amyloid-Related Imaging Abnormality (ARIA), occur with mAb therapy.
• Mechanisms of spontaneous and mAb-induced ARIA, particularly ARIA with edema/effusion (ARIA-E) and ARIA with hemorrhage (ARIA-H), require further investigation.

Purpose of the Study:

• To explore the mechanisms of spontaneous ARIA and mAb-induced ARIA.
• To examine the role of genetic variants, such as APOE-ε4 and TREM2, in ARIA development.
• To understand how these factors influence the safety and efficacy of AD treatments.

Main Methods:

• Review of existing literature on Alzheimer's disease, monoclonal antibodies, and ARIA.
• Analysis of the interplay between amyloid-beta (Aβ) deposition, immune responses, and genetic factors.
• Examination of the influence of APOE-ε4 and TREM2 on microglial reactivity and vascular integrity.

Main Results:

• Autoantibody-Aβ-mediated immune responses targeting Aβ deposits contribute to spontaneous ARIA.
• APOE-ε4 carriers show increased risk of ARIA-E due to Aβ redistribution to vasculature, while potentially reducing ARIA-H risk.
• Increased TREM2 expression and microglial reactivity are linked to ARIA-H by impairing vascular integrity.

Conclusions:

• ARIA mechanisms involve complex interactions between Aβ, immune responses, and host genetics.
• Understanding genetic influences like APOE-ε4 and TREM2 is crucial for predicting and managing ARIA in AD patients.
• Further research is needed to explore ARIA beyond APOE-ε4 and its implications for broader mAb-based AD therapies.